The latest research from the Mayo Clinic and Wayne State University has uncovered a fascinating potential synergy between a popular weight-loss drug and menopausal hormone therapy. This combination appears to supercharge weight loss in older women, offering a glimmer of hope in the ongoing battle against midlife weight gain.
The study, published in The Lancet Obstetrics, Gynaecology, & Women's Health, involved 120 women, primarily in their 50s and of White ethnicity. Half of the participants used tirzepatide, a GLP-1-based drug sold under the brand names Zepbound or Mounjaro, for weight loss. The other half used tirzepatide in conjunction with menopausal hormone therapy.
The results were striking. Women on both tirzepatide and hormone therapy lost an average of 19.2% of their starting body weight, a 5.2 percentage-point increase over those taking only tirzepatide. This difference is statistically significant, indicating a potential breakthrough in weight-loss treatment.
What makes this finding even more intriguing is the context of menopause. Menopause brings about a monumental transition, marked by widespread hormonal shifts and various physical symptoms like fatigue, hot flashes, and low libido. Menopause hormone therapy, which aims to replace lost hormones, has been shown to offer some protection from menopause-associated illnesses like osteoporosis and heart disease.
However, the relationship between menopause, hormone therapy, and weight loss has been historically underfunded and under-researched. Weight gain is a common issue for both pre- and post-menopausal women, often linked to reproductive issues and insulin problems. Patients with polycystic ovary syndrome, for instance, face a higher risk of type 2 diabetes and subsequent weight gain.
The study's authors, including lead researcher Regina Castaneda, caution that more research is needed. They highlight the importance of conducting controlled, randomized studies to understand the underlying mechanisms of this drug synergy. Castaneda points to initial studies in rodents suggesting that estrogen treatments can enhance GLP-1 signaling, but results are inconsistent.
Maria Daniela Hurtado Andrade, an endocrinologist and senior author, offers a nuanced perspective. She suggests that women using hormone therapy might already be engaged in healthier behaviors or that symptom relief from menopause could improve sleep and quality of life, making it easier to adopt healthier habits.
Looking ahead, Hurtado Andrade and her team plan to conduct a randomized controlled trial to explore the broader benefits of this drug combo. They aim to determine if hormone therapy enhances the effects of GLP-1 drugs on cardiometabolic measures, potentially offering a more comprehensive approach to weight management and overall health for postmenopausal women.
